Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.60 |
| ▸ | ACE | P12821 | 3/20 | 0.60 |
| ▸ | CPA1 | P15085 | 3/20 | 0.60 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ITGA4 | P13612 | 9/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2781125 | 1.00 | MME (0.60) | MMEACECPA1ACE2KMT2A | |
| SCHEMBL2781114 | 0.92 | MME (0.56) | MMEACECPA1ACE2KMT2A | |
| SCHEMBL2778799 | 0.92 | MME (0.56) | MMEACECPA1ACE2KMT2A | |
| SCHEMBL2779649 | 0.87 | MME (0.48) | MMEACECPA1ACE2KMT2A | |
| SCHEMBL503474 | 0.86 | ACE (0.57) | MMEACECPA1ACE2KMT2A | |
| SCHEMBL6170513 | 0.86 | ACE (0.57) | MMEACECPA1ACE2KMT2A | |
| SCHEMBL11148829 | 0.85 | MME (0.57) | MMEACECPA1ACE2KMT2A | |
| SCHEMBL11148836 | 0.82 | MME (0.54) | MMEACECPA1ACE2KMT2A | |
| SCHEMBL3007767 | 0.82 | PPARG (0.48) | MMEACECPA1ACE2ITGA4 | |
| SCHEMBL16267725 | 0.82 | CTSS (0.55) | MMEACECPA1ACE2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3113780-B1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-2632895-B1 | HIV PROTEASE INHIBITORS | MERCK CANADA INC (CA) | 2018-10-03 | — | — | EP | disclosed |
| US-9994587-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9834526-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9737545-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170217986-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-08-03 | — | — | US | disclosed |
| US-20160311786-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | disclosed |
| EP-2895482-B1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20160296527-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | US | disclosed |
| EP-2771332-B1 | Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS | MERCK CANADA INC (CA) | 2016-06-29 | — | — | EP | disclosed |
| EP-2258681-B1 | Aromatic Derivatives as HIV Aspartyl Protease Inhibitors | TAIMED BIOLOG INC (TW) | 2012-09-26 | — | — | EP | disclosed |
| EP-2258680-A2 | Aromatic derivatives as HIV aspartyl protease inhibitors | Ambrilia Biopharma Inc. (CA) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258681-A2 | Aromatic Derivatives as HIV Aspartyl Protease Inhibitors | Ambrilia Biopharma Inc. (CA) | 2010-12-08 | — | — | EP | disclosed |
| EP-2203420-A1 | HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20100093811-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-04-15 | — | — | US | disclosed |
| WO-2009042094-A2 | HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009042093-A1 | HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| EP-1575914-A1 | AROMATIC DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | Procyon Biopharma Inc. (CA) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004056764-A1 | AROMATIC DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | PROCYON BIOPHARMA INC. (CA) | 2004-07-08 | — | — | WO | disclosed |
| US-6632816-B1 | Aromatic derivatives as HIV aspartyl protease inhibitors | PHARMACOR INC. (CA) | 2003-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093811-A1 | HIV PROTEASE INHIBITORS | PRSS1, FURIN, SERPINB1 | MME 259/4885ACE 76/4885CPA1 66/4885 |
| US-20160296527-A1 | HIV PROTEASE INHIBITORS | PREP, PRSS1, PEPD | MME 24/4885ACE 16/4885CPA1 181/4885 |
| US-20160311786-A1 | HIV PROTEASE INHIBITORS | PREP, PRSS1, CTSV | MME 33/4885ACE 15/4885CPA1 221/4885 |
| US-20170217986-A1 | HIV PROTEASE INHIBITORS | CTSV, PRSS1, PREP | MME 77/4885ACE 34/4885CPA1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.